Tuesday, December 11, 2012

New America Folio Position Low Down: Celgene (CELG)


Celgene (CELG)

Celgene develops cancer and immune-inflammatory related drugs. With a market cap of $33.5 billion, it's among the most valuable companies in Investor's Business Daily's 234-stock Medical-Biomedical/Biotech group. 

On Nov. 9 Celgene announced positive results from an early-stage study of its new Abraxane drug to treat pancreatic cancer.

The biotech's Earnings Per Share (EPS)  jumped 26% last quarter to $1.29. It's posted double-digit profit growth every quarter for more than four years.

No comments:

Post a Comment